ORG Wealth Partners LLC Lowers Holdings in DaVita Inc. (NYSE:DVA)

ORG Wealth Partners LLC lowered its position in shares of DaVita Inc. (NYSE:DVA – Free Report) by 15.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 503 shares of the company’s stock after selling 89 shares during the period. ORG Wealth Partners LLC’s holdings in DaVita were worth $75,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. CWA Asset Management Group LLC grew its holdings in DaVita by 29.8% during the 4th quarter. CWA Asset Management Group LLC now owns 3,518 shares of the company’s stock worth $526,000 after acquiring an additional 808 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after purchasing an additional 12,339 shares in the last quarter. GAMMA Investing LLC increased its holdings in DaVita by 20.7% during the fourth quarter. GAMMA Investing LLC now owns 1,587 shares of the company’s stock valued at $237,000 after buying an additional 272 shares during the period. Versant Capital Management Inc raised its stake in DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after buying an additional 169 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on DVA shares. Barclays lifted their price target on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Truist Financial boosted their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $161.80.

Get Our Latest Stock Analysis on DaVita

DaVita Trading Down 0.5 %

Shares of NYSE:DVA opened at $153.20 on Friday. The business’s 50-day moving average is $155.41 and its 200 day moving average is $151.89. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a 1 year low of $103.40 and a 1 year high of $169.51. The firm has a market capitalization of $12.56 billion, a P/E ratio of 16.53, a P/E/G ratio of 0.86 and a beta of 0.92.

DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.85 EPS. On average, research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

About DaVita

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Articles

• Five stocks we like better than DaVita
• Investing in Construction Stocks
• Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
• When to Sell a Stock for Profit or Loss
• Why Amazon’s Next Earnings Could Trigger a Stock Breakout
• Breakout Stocks: What They Are and How to Identify Them
• With This Kind of Data, The Fed Isn’t Cutting Rates This Year

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).